Canadian cardiovascular drug development company Milestone Pharmaceuticals has initiated a Phase 1 clinical trial of its lead product, MSP-2017 intranasal short-acting calcium channel antagonist for the treatment of paroxysmal supraventricular tachycardia (PSVT), the company announced. The randomized, double-blind, placebo-controlled crossover study will take place in Australia and is designed to assess single ascending doses of two intranasal formulations of MSP-2017.
According to the company’s website, “The product is being developed as a nasal spray to provide for rapid systemic drug delivery to be used by ECG-diagnosed patients to terminate PSVT episodes, as they arise at-home in an unmonitored setting.”
Milestone CEO Philippe Douville commented, “MSP-2017 addresses an unmet medical need because there are no short-acting products for terminating PSVT episodes in the at-home setting, requiring most patients developing this arrhythmia to have to go to the emergency room for treatment with intravenous medications. The treatment could provide patients with an alternative to catheter ablation and might also be used in lieu of chronic pharmacologic therapy for patients with mild to moderate symptoms.”
Read the Milestone press release.
